Devert-50/Devert-100 Adverse Reactions

See table.

Click on icon to see table/diagram/image

Ischemic Cardiac Adverse Events: In clinical studies, there were uncommon reports of ischemic cardiac adverse events, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during treatment with desvenlafaxine compared with placebo.
Serum Lipids: Increased LDL (low density lipoprotein) cholesterol, fasting serum total cholesterol, and triglycerides were reported in patients taking Desvenlafaxine.
Adverse Reactions Leading to Discontinuation of Treatment: The most common adverse drug reactions leading to discontinuation in at least 2% of the patients treated with Desvenlafaxine were nausea, dizziness, headache & vomiting. At a recommended dose of 50 mg, the discontinuation rate due to adverse drug reactions is 4.1% as for 100 mg the discontinuation rate due to adverse drug reactions is 8.7%.
Discontinuation Symptoms: Adverse drug reactions in association with abrupt discontinuation, dose reduction or gradual discontinuation of treatment in MDD clinical studies at a rate ≥2% include dizziness, withdrawal syndrome, nausea, and headache. In general, the symptoms of discontinuation occurred more frequently at higher doses and longer duration of therapy.
Residual Inert Matrix of the Tablet: Patients taking Desvenlafaxine can find the inert matrix of the tablet in the stool or via colostomy. If this occurs, these patients should be informed that the active ingredient of the drug has already been absorbed.
Adverse Drug Reactions with Other SNRIs: Although gastrointestinal bleeding is not considered an adverse reaction to Desvenlafaxine, it is an adverse reaction to other SNRIs and may also occur with Desvenlafaxine.